What is FTH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.67B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FTH?

P/E (TTM) is n/a and 52-week range is $13.43 to $42.14 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FTH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FTH?

The company profile lists net income (TTM) near $-3.65B, EPS (TTM) near $-141.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Faeth Therapeutics, Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 25.8M shares outstanding, ISIN US81728A2078 when available from company profile and filing metadata.

Faeth Therapeutics, Inc

$FTH

Health Care · Biotechnology

IR Run Scenarios

$26.03

+1.64%

Faeth Therapeutics, Inc

$FTH

Health Care · Biotechnology

IR Run Scenarios

$26.03

+1.64%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.

Employees

29

Website

www.senseibio.com

IPO

2021-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US81728A2078

Headquarters

Austin, Texas, US

Shares outstanding

25.8M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

78.16%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.

Employees

29

Website

www.senseibio.com

IPO

2021-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)